Procyon Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Procyon Advisors’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-750	Closed	-$4K	–	1132
2020 Q2	$4K	Buy	+750	New	+$3.13K	﹤0.01%	842

Other funds holding ISEE

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Procyon Advisors's ISEE Position: Q3 2020 in Review

Procyon Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2020, closing a stake of 750 shares — an estimated $4K sold.

Procyon Advisors first reported a position in ISEE in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 101 funds tracked by Wall St. Rank hold ISEE as of Q3 2020.

Procyon Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Procyon Advisors sold 750 IVERIC bio, Inc. Common Stock shares in Q3 2020, an estimated $4K.
Procyon Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
Procyon Advisors's IVERIC bio, Inc. Common Stock position peaked at $4K in Q2 2020.
101 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.